亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

罗米普洛斯蒂姆 医学 血小板减少性紫癜 安慰剂 临床终点 内科学 血小板生成素 血小板生成素 随机对照试验 临床试验 胃肠病学 血小板 巨核细胞 遗传学 替代医学 干细胞 病理 造血 生物
作者
David J. Kuter,James B. Bussel,Roger M. Lyons,Vinod Pullarkat,Terry Gernsheimer,Francis M. Senecal,Louis M. Aledort,James N. George,Craig M. Kessler,Miguel Á. Sanz,Howard A. Liebman,Frank T. Slovick,J. Th. M. de Wolf,Emmanuelle Bourgeois,Troy H. Guthrie,Adrian C. Newland,Jeffrey S. Wasser,Solomon I. Hamburg,Carlos Grande,François Lefrère
出处
期刊:The Lancet [Elsevier BV]
卷期号:371 (9610): 395-403 被引量:844
标识
DOI:10.1016/s0140-6736(08)60203-2
摘要

Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction and decreased platelet production. Short-term administration of the thrombopoiesis-stimulating protein, romiplostim, has been shown to increase platelet counts in most patients with chronic ITP. We assessed the long-term administration of romiplostim in splenectomised and non-splenectomised patients with ITP.In two parallel trials, 63 splenectomised and 62 non-splenectomised patients with ITP and a mean of three platelet counts 30x10(9)/L or less were randomly assigned 2:1 to subcutaneous injections of romiplostim (n=42 in splenectomised study and n=41 in non-splenectomised study) or placebo (n=21 in both studies) every week for 24 weeks. Doses of study drug were adjusted to maintain platelet counts of 50x10(9)/L to 200x10(9)/L. The primary objectives were to assess the efficacy of romiplostim as measured by a durable platelet response (platelet count > or =50x10(9)/L during 6 or more of the last 8 weeks of treatment) and treatment safety. Analysis was per protocol. These studies are registered with ClinicalTrials.gov, numbers NCT00102323 and NCT00102336.A durable platelet response was achieved by 16 of 42 splenectomised patients given romplostim versus none of 21 given placebo (difference in proportion of patients responding 38% [95% CI 23.4-52.8], p=0.0013), and by 25 of 41 non-splenectomised patients given romplostim versus one of 21 given placebo (56% [38.7-73.7], p<0.0001). The overall platelet response rate (either durable or transient platelet response) was noted in 88% (36/41) of non-splenectomised and 79% (33/42) of splenectomised patients given romiplostim compared with 14% (three of 21) of non-splenectomised and no splenectomised patients given placebo (p<0.0001). Patients given romiplostim achieved platelet counts of 50x10(9)/L or more on a mean of 13.8 (SE 0.9) weeks (mean 12.3 [1.2] weeks in splenectomised group vs 15.2 [1.2] weeks in non-splenectomised group) compared with 0.8 (0.4) weeks for those given placebo (0.2 [0.1] weeks vs 1.3 [0.8] weeks). 87% (20/23) of patients given romiplostim (12/12 splenectomised and eight of 11 non-splenectomised patients) reduced or discontinued concurrent therapy compared with 38% (six of 16) of those given placebo (one of six splenectomised and five of ten non-splenectomised patients). Adverse events were much the same in patients given romiplostim and placebo. No antibodies against romiplostim or thrombopoietin were detected.Romiplostim was well tolerated, and increased and maintained platelet counts in splenectomised and non-splenectomised patients with ITP. Many patients were able to reduce or discontinue other ITP medications. Stimulation of platelet production by romiplostim may provide a new therapeutic option for patients with ITP.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
11秒前
xingsixs完成签到,获得积分10
22秒前
星辰大海应助科研通管家采纳,获得10
1分钟前
1分钟前
邓权发布了新的文献求助10
1分钟前
娇气的幼南完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
生动之云发布了新的文献求助10
1分钟前
2分钟前
2分钟前
美好颜发布了新的文献求助10
2分钟前
2分钟前
大模型应助科研通管家采纳,获得10
3分钟前
小二郎应助科研通管家采纳,获得10
3分钟前
Betty发布了新的文献求助10
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
慕青应助lty采纳,获得10
4分钟前
4分钟前
4分钟前
lty发布了新的文献求助10
4分钟前
小岩完成签到 ,获得积分10
4分钟前
4分钟前
咕咕发布了新的文献求助10
4分钟前
彩色黑米完成签到 ,获得积分10
4分钟前
科研通AI2S应助科研通管家采纳,获得10
4分钟前
5分钟前
5分钟前
AKi233完成签到,获得积分10
5分钟前
AKi233发布了新的文献求助10
5分钟前
充电宝应助AKi233采纳,获得10
5分钟前
咕咕完成签到,获得积分10
5分钟前
FengyaoWang完成签到,获得积分10
5分钟前
6分钟前
传奇3应助科研通管家采纳,获得10
6分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968504
求助须知:如何正确求助?哪些是违规求助? 3513278
关于积分的说明 11167234
捐赠科研通 3248660
什么是DOI,文献DOI怎么找? 1794386
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804638